Loading...
Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis
Saadi, Md Sadman Sakib Das, Rajib Mullath Ullas, Adhithya Powell, Diane E. Wilson, Emma Myrtziou, Ioanna Rakieh, Chadi Kanakis, Ioannis
Saadi, Md Sadman Sakib
Das, Rajib
Mullath Ullas, Adhithya
Powell, Diane E.
Wilson, Emma
Myrtziou, Ioanna
Rakieh, Chadi
Kanakis, Ioannis
Citations
Altmetric:
Advisors
Editors
Other Contributors
EPub Date
Publication Date
2024-07-22
Submitted Date
Collections
Files
Loading...
Article - VoR
Adobe PDF, 4.25 MB
Other Titles
Abstract
Diabetic bone disease (DBD) is a frequent complication in patients with type 2 diabetes mellitus (T2DM), characterised by altered bone mineral density (BMD) and bone turnover marker (BTMs) levels. The impact of different anti-diabetic medications on the skeleton remains unclear, and studies have reported conflicting results; thus, the need for a comprehensive systematic review is of paramount importance. A systematic search was conducted in PubMed and the Cochrane Library. The primary outcomes assessed were changes in BMD in relation to different anatomical sites and BTMs, including mainly P1NP and CTX as well as OPG, OCN, B-ALP and RANK-L. Risk of bias was evaluated using the JADAD score. The meta-analysis of 19 randomised controlled trials comprising 4914 patients showed that anti-diabetic medications overall increased BMD at the lumbar spine (SMD: 0.93, 95% CI [0.13, 1.73], p = 0.02), femoral neck (SMD: 1.10, 95% CI [0.47, 1.74], p = 0.0007) and in total hip (SMD: 0.33, 95% CI [−0.25, 0.92], p = 0.27) in comparison with placebo, but when compared with metformin, the overall effect favoured metformin over other treatments (SMD: −0.23, 95% CI [−0.39, −0.07], p = 0.004). GLP-1 receptor agonists and insulin analogues seem to improve BMD compared to placebo, while SGLT2 inhibitors and thiazolidinediones (TZDs) showed no significant effect, although studies’ number cannot lead to safe conclusions. For BTMs, TZDs significantly increased P1NP levels compared to placebo. However, no significant differences were observed for CTX, B-ALP, OCN, OPG, and RANK-L between anti-diabetic drugs and metformin or placebo. High heterogeneity and diverse follow-up durations among studies were evident, which obscures the validity of the results. This review highlights the variable effects of anti-diabetic drugs on DBD in T2DM patients, emphasising the need for long-term trials with robust designs to better understand these relationships and inform clinical decisions.
Citation
Saadi, M. S. S., Das, R., Mullath Ullas, A., Powell, D. E., Wilson, E., Myrtziou, I., Rakieh, C., & Kanakis, I. (2024). Impact of different anti-hyperglycaemic treatments on bone turnover markers and bone mineral density in Type 2 diabetes mellitus patients: A systematic review and meta-analysis. International Journal of Molecular Sciences, 25(14), article-number 7988. https://doi.org/10.3390/ijms25147988
Publisher
MDPI
Journal
International Journal of Molecular Sciences
Research Unit
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
© 2024 by the authors. Licensee MDPI, Basel, Switzerland.
Series/Report no.
ISSN
1661-6596
EISSN
1422-0067
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
University of Chester QRFund